| SC 13G/A | 2019-02-13 | New Leaf Biopharma Opportunities II, L.P. | Aravive, Inc. | 970,659 | 8.7% | EDGAR |
| SC 13D | 2018-10-22 | Liu Qianye | Aravive, Inc. | 859,766 | 7.7% | EDGAR |
| SC 13D | 2018-10-19 | Tabibiazar Raymond | Aravive, Inc. | 1,635,585 | 13.8% | EDGAR |
| SC 13D | 2018-10-19 | Zhang Eric | Aravive, Inc. | 859,766 | 7.7% | EDGAR |
| SC 13D | 2018-10-19 | Giaccia Amato | Aravive, Inc. | 1,162,608 | 10.2% | EDGAR |
| SC 13G | 2018-07-24 | New Leaf Biopharma Opportunities II, L.P. | Versartis, Inc. | 2,247,000 | 6.2% | EDGAR |
| SC 13G/A | 2018-07-10 | BlackRock Inc. | Versartis, Inc. | 1,131,168 | 3.1% | EDGAR |
| SC 13D | 2018-06-18 | AKKARAJU SRINIVAS | Versartis, Inc. | 2,656,399 | 7.4% | EDGAR |
| SC 13G/A | 2018-02-14 | PERCEPTIVE ADVISORS LLC | Versartis, Inc. | 1,488,160 | 4.2% | EDGAR |
| SC 13G | 2018-02-14 | Index Ventures IV (Jersey) LP | Versartis, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-13 | BAKER BROS. ADVISORS LP | Versartis, Inc. | 1,426,310 | 4.0% | EDGAR |
| SC 13G | 2018-02-08 | Advent Life Sciences LLP | Versartis, Inc. | 1,621,558 | 4.5% | EDGAR |
| SC 13G/A | 2018-02-07 | AISLING CAPITAL III LP | Versartis, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-01-23 | BlackRock Inc. | Versartis, Inc. | 2,026,814 | 5.7% | EDGAR |
| SC 13G/A | 2017-10-10 | FMR LLC | Versartis, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2017-09-26 | PERCEPTIVE ADVISORS LLC | Versartis, Inc. | 2,099,563 | 5.9% | EDGAR |
| SC 13D/A | 2017-03-28 | New Leaf Ventures II, L.P. | Versartis, Inc. | - | - | EDGAR |
| SC 13D/A | 2017-03-17 | Sofinnova Venture Partners VIII, L.P. | Versartis, Inc. | 1,658,865 | 4.7% | EDGAR |
| SC 13D/A | 2017-03-13 | Sofinnova Venture Partners VIII, L.P. | Versartis, Inc. | 1,980,412 | 5.7% | EDGAR |
| SC 13G/A | 2017-02-14 | FMR LLC | Versartis, Inc. | 4,128,376 | 11.9% | EDGAR |